Radical retropublc prostatectomy for localized carcinoma of the prostate in a large metropolitan hospital: Changing trends over a 10-year period (1984–1994)

Litwiller, Scott E.; Richier, John C.; Djavan, Babak; Roehrborn, Claus G.; Klopukh, Boris

doi:10.1016/s0090-4295(99)80089-2

Cited by 35 publications

(20 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We also registered a substantial shift toward local tumor stages: in 1999, the proportion of local prostate cancers was 66.9%, whereas in 1995, this rate was only 30.4%. This is well in line with reports from other clinics: in the USA, this proportion was [60% by 1995 [13]. However, this does not reflect an increase in patients with histologically insignificant tumors but a rising number of patients with significant tumors in a pT2 stage.…”

Section: Discussionsupporting

confidence: 92%

Impact of preoperative antiandrogen medication and nerve-sparing surgery on the outcome of radical prostatectomy

et al. 2008

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 92%

Impact of preoperative antiandrogen medication and nerve-sparing surgery on the outcome of radical prostatectomy

et al. 2008

View full text Add to dashboard Cite

show abstract

“…In another older series of 428 RPs performed between 1984 and 1994, Litwiller et al had already found a decrease in the average age of patients from 67 to 63 years [17]. Interestingly, we detected no clear trend to younger ages at surgery in our patient cohort.…”

Section: Discussioncontrasting

confidence: 63%

Shift of tumor features in patients with clinically localized prostate cancer undergoing radical prostatectomy since the beginning of the PSA era

Augustin

Auprich

Stummvoll

et al. 2006

Wien Klin Wochenschr

View full text Add to dashboard Cite

show abstract

“…Stage migration towards lower clinical and pathological stage has been demonstrated in other countries (Litwiller et al, 1995;Moul et al, 2002) and likewise this has led to an improvement in overall PSA recurrence-free survival rates (Moul et al, 2002;Ung et al, 2002;Freedland et al, 2003). The changes of pathological stage proportions have an impact on overall PSA recurrence-free survival.…”

Section: Discussionmentioning

confidence: 90%

Contemporary update of cancer control after radical prostatectomy in the UK

et al. 2004

View full text Add to dashboard Cite

5Bristol Royal Inf irmary, UK Despite a significant increase of the number of radical prostatectomies (RPs) to treat organ-confined prostate cancer, there is very limited documentation of its oncological outcome in the UK. Pathological stage distribution and changes of outcome have not been audited on a consistent basis. We present the results of a multicentre review of postoperative predictive variables and prostaticspecific antigen (PSA) recurrence after RP for clinically organ-confined disease. In all, 854 patient's notes were audited for staging parameters and follow-up data obtained. Patients with neoadjuvant and adjuvant treatment as well as patients with incomplete data and follow-up were excluded. Median follow-up was 52 months for the remaining 705 patients. The median PSA was 10 ng ml À1 . A large migration towards lower PSA and stage was seen. This translated into improved PSA survival rates. Overall Kaplan -Meier PSA recurrence-free survival probability at 1, 3, 5 and 8 years was 0.83, 0.69, 0.60 and 0.48, respectively. The 5-year PSA recurrence-free survival probability for PSA ranges o4, 4.1 -10, 10.1 -20 and 420 ng ml À1 was 0.82, 0.73, 0.59 and 0.20, respectively (log rank, Po0.0001). PSA recurrence-free survival probabilities for pathological Gleason grade 2 -4, 5 and 6, 7 and 8 -10 at 5 years were 0.84, 0.66, 0.55 and 0.21, respectively (log rank, Po0.0001). Similarly, 5-year PSA recurrence-free survival probabilities for pathological stages T2a, T2b, T3a, T3b and T4 were 0.82, 0.78, 0.48, 0.23 and 0.12, respectively (log rank, P ¼ 0.0012). Oncological outcome after RP has improved over time in the UK. PSA recurrence-free survival estimates are less optimistic compared to quoted survival figures in the literature. Survival figures based on pathological stage and Gleason grade may serve to counsel patients postoperatively and to stratify patients better for adjuvant treatment.

show abstract

Radical retropublc prostatectomy for localized carcinoma of the prostate in a large metropolitan hospital: Changing trends over a 10-year period (1984–1994)

Cited by 35 publications

References 17 publications

Impact of preoperative antiandrogen medication and nerve-sparing surgery on the outcome of radical prostatectomy

Impact of preoperative antiandrogen medication and nerve-sparing surgery on the outcome of radical prostatectomy

Shift of tumor features in patients with clinically localized prostate cancer undergoing radical prostatectomy since the beginning of the PSA era

Contemporary update of cancer control after radical prostatectomy in the UK

Contact Info

Product

Resources

About